Discovery of SZJK-0421: A Novel Potent, Low Toxicity, Selective Second Generation of CRM1 Inhibitor for the Treatment of Both Hematological and Solid TumorsClick to copy article linkArticle link copied!
- Hang MiaoHang MiaoCollege of Life Science, Nanjing Normal University, No. 1 Wenyuan Road, Nanjing 210037, P. R. ChinaMore by Hang Miao
- Yanru QinYanru QinCollege of Life Science, Nanjing Normal University, No. 1 Wenyuan Road, Nanjing 210037, P. R. ChinaMore by Yanru Qin
- DingLu ShaoDingLu ShaoCollege of Life Science, Nanjing Normal University, No. 1 Wenyuan Road, Nanjing 210037, P. R. ChinaMore by DingLu Shao
- Qinghua ChenQinghua ChenCollege of Life Science, Nanjing Normal University, No. 1 Wenyuan Road, Nanjing 210037, P. R. ChinaMore by Qinghua Chen
- Yupeng PanYupeng PanCollege of Life Science, Nanjing Normal University, No. 1 Wenyuan Road, Nanjing 210037, P. R. ChinaMore by Yupeng Pan
- Meng LeiMeng LeiCollege of Science, Nanjing Forestry University, No. 159 Longpan Road, Nanjing 210037, P. R. ChinaMore by Meng Lei
- Ruokun WuRuokun WuCollege of Science, Nanjing Forestry University, No. 159 Longpan Road, Nanjing 210037, P. R. ChinaMore by Ruokun Wu
- Xinran YeXinran YeCollege of Science, Nanjing Forestry University, No. 159 Longpan Road, Nanjing 210037, P. R. ChinaMore by Xinran Ye
- Xueyuan Wang*Xueyuan Wang*Email: [email protected]College of Life Science, Nanjing Normal University, No. 1 Wenyuan Road, Nanjing 210037, P. R. ChinaMore by Xueyuan Wang
- Yongqiang Zhu*Yongqiang Zhu*Email: [email protected]College of Life Science, Nanjing Normal University, No. 1 Wenyuan Road, Nanjing 210037, P. R. ChinaMore by Yongqiang Zhu
Abstract
Nuclear export factor chromosome region maintenance 1 (CRM1) mediated the transport of various growth-regulatory proteins and was frequently overexpressed in many hematologic and solid tumors. Selinexor (KPT-330) was the only approved CRM1 inhibitor, but the severe gastrointestinal and central nervous system toxicities limited its clinical application. In this manuscript, a series of novel second-generation CRM1 inhibitors were designed, in which SZJK-0421 was a more reversible inhibitor than KPT-330. The treatment of various tumor cells with SZJK-0421 significantly inhibited the function of CRM1. SZJK-0421 displayed good liver microsome stabilities and pharmacokinetic properties. Most importantly, SZJK-0421 reduced the direct damage to the gastrointestinal mucosa, and the brain plasma distribution ratio of SZJK-0421 was very low in Sprague-Dawley (SD) rats (3%), which avoided gastrointestinal reactions such as central nausea and vomiting caused by large permeability of blood–brain barrier. In addition, SZJK-0421 exhibited strong anticancer efficacy in xenograft models of both solid and hematological tumors.
Cited By
This article has not yet been cited by other publications.
Article Views
Altmetric
Citations
Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.
Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.
The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated.